Cargando…

Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial

OBJECTIVE: We investigated the efficacy and toxicity of tailored-dose chemotherapy with gemcitabine and irinotecan for platinum-refractory/resistant ovarian or primary peritoneal cancer. METHODS: We enrolled patients with ovarian or primary peritoneal cancer who received ≥2 previous chemotherapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tate, Shinichi, Nishikimi, Kyoko, Matsuoka, Ayumu, Otsuka, Satoyo, Kato, Kazuyoshi, Takahashi, Yutaka, Shozu, Makio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767653/ https://www.ncbi.nlm.nih.gov/pubmed/33185049 http://dx.doi.org/10.3802/jgo.2021.32.e8

Ejemplares similares

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
por: Tate, Shinichi, et al.
Publicado: (2021)

Surgical Techniques and Outcomes of Colorectal Anastomosis after Left Hemicolectomy with Low Anterior Rectal Resection for Advanced Ovarian Cancer
por: Nishikimi, Kyoko, et al.
Publicado: (2021)

Predictors of postoperative pancreatic fistula after splenectomy with or without distal pancreatectomy performed as a component of cytoreductive surgery for advanced ovarian cancer
por: Nishikimi, Kyoko, et al.
Publicado: (2022)

Aggressive surgery could overcome the extent of initial peritoneal dissemination for advanced ovarian, fallopian tube, and peritoneal carcinoma
por: Nishikimi, Kyoko, et al.
Publicado: (2020)

Serum FSH as a Useful Marker for the Differential Diagnosis of Ovarian Granulosa Cell Tumors
por: Matsuoka, Ayumu, et al.
Publicado: (2022)

Well-trained gynecologic oncologists can perform bowel resection and upper abdominal surgery safely
por: Nishikimi, Kyoko, et al.
Publicado: (2019)

Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer
por: Tate, Shinichi, et al.
Publicado: (2019)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
por: Tate, Shinichi, et al.
Publicado: (2021)

Surgical anatomy of the common iliac veins during para-aortic and pelvic lymphadenectomy for gynecologic cancer
por: Kato, Kazuyoshi, et al.
Publicado: (2014)

Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration
por: Kato, Kazuyoshi, et al.
Publicado: (2015)

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
por: Ioka, T, et al.
Publicado: (2017)

Bexarotene-induced cell death in ovarian cancer cells through Caspase-4-gasdermin E mediated pyroptosis
por: Kobayashi, Tatsuya, et al.
Publicado: (2022)

A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
por: Nagao, Shoji, et al.
Publicado: (2020)

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
por: Ko, A H, et al.
Publicado: (2013)

Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas
por: Ramella Munhoz, Rodrigo, et al.
Publicado: (2013)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
por: Wilbur, H. Catherine, et al.
Publicado: (2023)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma
por: Ulrich-Pur, H, et al.
Publicado: (2003)

Modified Leak-Proof Puncture Technique for the Aspiration of Giant Ovarian Cysts by Instantly Mounting a Plastic Wrap and Gauze with Cyanoacrylates: A Retrospective Observational Study
por: Ishikawa, Hiroshi, et al.
Publicado: (2022)

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
por: Ak, Guntulu, et al.
Publicado: (2015)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Is the blood of a surgeon performing HIPEC contaminated by irinotecan, its major metabolites and platinum compounds?
por: Saint-Lorant, Guillaume, et al.
Publicado: (2021)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma
por: Imaya, Masayuki, et al.
Publicado: (2022)

Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature
por: XU, QIUYI, et al.
Publicado: (2013)

Peritoneal Dialysis Tailored to Pediatric Needs
por: Schmitt, C. P., et al.
Publicado: (2011)

Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial
por: Holtan, Shernan G., et al.
Publicado: (2012)

CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan
por: Blume, Joshua, et al.
Publicado: (2023)

Outcomes and Prognostic Factors of Patients with Platinum-Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer
por: Hamontri, Suttha, et al.
Publicado: (2023)

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
por: Ueno, H, et al.
Publicado: (2007)

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
por: Stathopoulos, G P, et al.
Publicado: (2006)

Molecular Bases and Phenotypic Determinants of Aromatase Excess Syndrome
por: Fukami, Maki, et al.
Publicado: (2012)

Understanding the pathological manifestations of aromatase excess syndrome: lessons for clinical diagnosis
por: Shozu, Makio, et al.
Publicado: (2014)

Aromatase excess syndromeas a model for genomic disorder: identification of molecular bases and phenotypic determinants
por: Ogata, Tsutomu, et al.
Publicado: (2013)

Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer
por: Hanawa, Shinsuke, et al.
Publicado: (2018)

Parental contribution to trisomy in heterozygous androgenetic complete moles
por: Usui, Hirokazu, et al.
Publicado: (2020)

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
por: Suzuki, Eiichiro, et al.
Publicado: (2013)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_4u5j0duiuvcmochrdqdi7rs0hs